Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Meningococcal vaccine groups A C Y W-135 conjugate - Pfizer

Drug Profile

Meningococcal vaccine groups A C Y W-135 conjugate - Pfizer

Alternative Names: GSK 134612; MenACWY - GlaxoSmithKline; MenACWY conjugated vaccine - GlaxoSmithKline; MenACWY-TT; Nimenrix

Latest Information Update: 13 Mar 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Class Conjugate vaccines; Meningococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Meningococcal infections

Most Recent Events

  • 13 Mar 2019 Launched for Meningococcal infections (Prevention) in South Africa, prior March 2019 (IM)
  • 13 Mar 2019 Registered for Meningococcal infections (Prevention) in South Africa, prior March 2019 (IM)
  • 01 Aug 2018 GlaxoSmithKline completes a phase III extension trial for Meningococcal infections (Prevention) in Philippines (IM) (NCT01934140)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top